Brief: Corvus Pharmaceuticals Announces Interim Data From Phase 1 Trial Of Soquelitinib For Atopic Dermatitis
18/12/2024 12:58
Dec 18 (Reuters) - Corvus Pharmaceuticals Inc CRVS.O :
* CORVUS PHARMACEUTICALS ANNOUNCES INTERIM DATA FROM
PLACEBO-CONTROLLED PHASE 1 CLINICAL TRIAL OF SOQUELITINIB FOR
ATOPIC DERMATITIS
* LOWEST DOSE LEVEL COHORTS SHOW FAVORABLE SAFETY AND
EFFICACY
Source text: ID:nGNXcTwqw
Further company coverage: CRVS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Corvus Pharmaceuticals
See all newsBrief: Corvus Pharmaceuticals Announces Initiation Of Phase 1B Clinical Trial Of Soquelitinib For Patients With Hidradenitis Suppurativa
Corvus Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Toll Brothers, TG Therapeutics, CECO Environmental